Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 227

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012

Open access
Venning, V.A., Taghipour, K., Mohd Mustapa, M.F., Highet, A.S., Kirtschig, G., Hughes, J.R., McLelland, J., McDonagh, A.J., Punjabi, S., Buckley, D.A., Nasr, I., Swale, V.J., Duarte Williams, C.E., McHenry, P.M., Wagle, S., Amin, S., Davis, R., Haveron, S.E. · 2012 · British Journal of Dermatology

Abstract

NHS Evidence has accredited the process used by the British Association of Dermatologists to produce guidelines. Accreditation is valid for 3 years from May 2010 and is applicable to guidance produced using the processes described in the British Association of Dermatologists’ guidelines development manual (Bell & Ormerod, 2009). More information on accreditation can be viewed at http://www.evidence.nhs.uk. The overall objective of the guideline is to provide up‐to‐date, evidence‐based recommendations for the management of bullous pemphigoid (BP). The document aims to update and expand on the previous guidelines by: (i) offering an appraisal of all relevant literature since January 2002, focusing on any key developments; (ii) addressing important, practical clinical questions relating to the primary guideline objective; (iii) providing guideline recommendations and, where appropriate, with some health economic implications discussing potential developments and future directions. The guideline is presented as a detailed review with highlighted recommendations for practical use in the clinic (see section 14.0), in addition to an updated patient information leaflet [available on the British Association of Dermatologists’ (BAD) website; http://www.bad.org.uk]. The guideline development group consisted of consultant dermatologists. The draft document was circulated to the BAD membership, the British Dermatological Nursing Group (BDNG), the Primary Care Dermatological Society (PCDS) and the Pemphigus Vulgaris Network for comments, and was peer reviewed by the Clinical Standards Unit of the BAD (made up of the Therapy and Guidelines subcommittee) prior to publication. This set of guidelines has been developed using the BAD’s recommended methodology1 and with reference to the Appraisal of Guidelines Research and Evaluation (AGREE II) instrument.2 Recommendations were developed for implementation in the National Health Service (NHS) using a process of considered judgment based on the evidence. PubMed, MEDLINE and EMBASE databases were searched up to June 2012 for meta‐analyses, randomized and nonrandomized controlled clinical trials, case series, case reports and open studies involving bullous pemphigoid, with no language exclusions; search terms and strategies are detailed in Appendix S1 online (see Supporting information). Additional relevant references were also isolated from citations in the reviewed literature, as well as (independent) targeted searches carried out by coauthors. Working in pairs, the authors screened the identified titles, and those relevant for first‐round inclusion were selected for further scrutiny. The abstracts for the shortlisted references were then reviewed and the full papers of relevant material were obtained; disagreements in the final selections were resolved by discussion with the entire development group. Additional selection criteria included relevant publications on the management of childhood BP. The structure of the 2002 guidelines was then discussed and re‐evaluated, and different coauthors were allocated separate subsections. Each coauthor then performed a detailed appraisal of the selected literature with discussions with the entire development group to resolve any issues, e.g. with the quality of evidence and making the appropriate recommendations. All subsections were subsequently collated and edited to produce the final guideline. This document has been prepared on behalf of the BAD and is based on the best data available when the document was prepared. It is recognized that under certain conditions it may be necessary to deviate from the guidelines and that the results of future studies may require some of the recommendations herein to be changed. Failure to adhere to these guidelines should not necessarily be considered negligent, nor should adherence to these recommendations constitute a defence against a claim of negligence. The proposed revision date for this set of recommendations is scheduled for 2017; where necessary, important interim changes will be updated on the BAD website. BP is an autoimmune subepidermal blistering disease that typically affects the elderly but may rarely present in children and younger adults. Autoantibodies of IgG type (and less commonly IgA, IgM and IgE) attack components of the adhesion complex of the basement membrane zone (BMZ) and result in subepidermal blistering. The two main autoantigens are BP230 (BPAg1) and BP180 (BPAg2, collagen XVII). BP is the most common immunobullous disease in Western Europe with a reported incidence of 43 per million per year in the U.K.3 and 7–13 per million per year in other parts of Europe.4–6 The mean age of onset is around 80 years. Recently it has been shown that BP is associated with neurological disease such as cerebrovascular disease, dementia, Parkinson disease, epilepsy and multiple sclerosis.7–10 These conditions pre‐date BP and hence are considered as risk factors. There are a number of anecd

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjd.12072

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 227

Metadata

Authors
Venning, V. A., Taghipour, K., Mohd Mustapa, M. F., Highet, A. S., Kirtschig, G., Hughes, J. R., McLelland, J., McDonagh, A. J., Punjabi, S., Buckley, D. A., Nasr, I., Swale, V. J., Duarte Williams, C. E., McHenry, P. M., Wagle, S., Amin, S., Davis, R., & Haveron, S. E.
Venue
British Journal of Dermatology
Published
2012-11-02
Volume
167
Issue
6
Pages
1200-1214
ISSN
  • 0007-0963 (ISSN-L)
  • 1365-2133
OpenAlex
W1684483569
Cited by
227
References
1
FWCI
6.86
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.